Brazilian dengue vaccine 80% effective after five years


By AGENCY
The single-dose dengue vaccine developed in Brazil shows continued strong protection against both severe and symptomatic dengue five years after administration. — Comunicação Butantan

The dengue vaccine developed by the Butantan Institute in São Paulo, Brazil was 80.5% effective against severe dengue cases over a five-year period.

It was also 65% effective in preventing symptomatic dengue.

The phase 3 clinical trial conducted at 16 research centres across Brazil involved 16,235 participants between the ages of two and 59 years.

Of those, 10,259 received a single dose of the vaccine, while 5,976 received a placebo.

There were no reports of hospitalisation in the vaccinated group, compared to eight cases in the placebo group.

Called Butantan-DV, the tetravalent vaccine protects against all four known serotypes of the dengue virus.

It uses live viruses that have been “weakened” (attenuated) in a laboratory setting so that they cannot cause disease, yet are still able to stimulate an immune response.

The vaccine was approved by the Brazilian Health Regulatory Agency (ANVISA) on Nov 26, 2025, for use in the Brazilian population aged 12 to 59.

The results of the clinical trial was published on March 4 (2026) in the journal Nature Medicine. – Agência FAPESP

Follow us on our official WhatsApp channel for breaking news alerts and key updates!
Dengue , vaccine , infectious diseases

Next In Health

Updates for prostate screening recommendation
Learning how to age well
BCG vaccine could help counter dementia
Surgery options for complex heart valve cases
Managing mum’s depression helps baby’s emotional development
Teaching children about 'safe touch'
Faking symptoms to get antibiotics
Premature babies: Their fight to survive�
Diabetic retinopathy: When diabetes steals your sight
Plant proteins can help boost testosterone

Air Pollutant Index

Note: API is calculated based on 24hr running average of the most dominant parameter.

Highest API Readings

    Select State and Location to view the latest API reading

    Others Also Read